| Autor: |
Astakhova EA; Laboratory of Immunochemistry, National Research Center Institute of Immunology, Federal Medical Biological Agency of Russia, 115522 Moscow, Russia.; Department of Immunology, Faculty of Biology, Lomonosov Moscow State University, 119234 Moscow, Russia., Morozov AA; Laboratory of Immunochemistry, National Research Center Institute of Immunology, Federal Medical Biological Agency of Russia, 115522 Moscow, Russia.; Department of Immunology, Faculty of Biology, Lomonosov Moscow State University, 119234 Moscow, Russia., Byazrova MG; Laboratory of Immunochemistry, National Research Center Institute of Immunology, Federal Medical Biological Agency of Russia, 115522 Moscow, Russia.; Department of Immunology, Faculty of Biology, Lomonosov Moscow State University, 119234 Moscow, Russia.; Ministry of Science and Higher Education of Russia, RUDN University, 117198 Moscow, Russia., Sukhova MM; Laboratory of Immunochemistry, National Research Center Institute of Immunology, Federal Medical Biological Agency of Russia, 115522 Moscow, Russia.; Department of Immunology, Faculty of Biology, Lomonosov Moscow State University, 119234 Moscow, Russia., Mikhailov AA; Laboratory of Immunochemistry, National Research Center Institute of Immunology, Federal Medical Biological Agency of Russia, 115522 Moscow, Russia.; Department of Immunology, Faculty of Biology, Lomonosov Moscow State University, 119234 Moscow, Russia., Minnegalieva AR; Laboratory of Synthetic and Evolutionary Biology, Okinawa Institute of Science and Technology, Okinawa 904-0495, Japan., Gorchakov AA; Laboratory of Immunogenetics, Institute of Molecular and Cellular Biology, Siberian Branch of the Russian Academy of Sciences, 630090 Novosibirsk, Russia., Filatov AV; Laboratory of Immunochemistry, National Research Center Institute of Immunology, Federal Medical Biological Agency of Russia, 115522 Moscow, Russia.; Department of Immunology, Faculty of Biology, Lomonosov Moscow State University, 119234 Moscow, Russia. |
| Abstrakt: |
The rapid emergence of evasive SARS-CoV-2 variants is an ongoing challenge for COVID-19 vaccinology. Traditional virus neutralization tests provide detailed datasets of neutralization titers against the viral variants. Such datasets are difficult to interpret and do not immediately inform of the sufficiency of the breadth of the antibody response. Some of these issues could be tackled using the antigenic cartography approach. In this study, we created antigenic maps using neutralization titers of sera from donors who received the Sputnik V booster vaccine after primary Sputnik V vaccination and compared them with the antigenic maps based on serum neutralization titers of Comirnaty-boosted donors. A traditional analysis of neutralization titers against the WT (wild-type), Alpha, Beta, Delta, Omicron BA.1, and BA.4/BA.5 variants showed a significant booster humoral response after both homologous (Sputnik V) and heterologous (Comirnaty) revaccinations against all of the studied viral variants. However, despite this, a more in-depth analysis using antigenic cartography revealed that Omicron variants remain antigenically distant from the WT, which is indicative of the formation of insufficient levels of cross-neutralizing antibodies. The implications of these findings may be significant when developing a new vaccine regimen. |
